United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Tidal Investments LLC

Tidal Investments LLC lifted its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 33.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,272 shares of the biotechnology company's stock after purchasing an additional 2,803 shares during the period. Tidal Investments LLC's holdings in United Therapeutics were worth $4,039,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock worth $652,000 after purchasing an additional 33 shares in the last quarter. Toronto Dominion Bank boosted its holdings in United Therapeutics by 0.8% in the 2nd quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock valued at $1,441,000 after purchasing an additional 37 shares during the period. ClariVest Asset Management LLC boosted its holdings in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. boosted its position in shares of United Therapeutics by 14.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock worth $109,000 after acquiring an additional 42 shares in the last quarter. Finally, First Citizens Bank & Trust Co. boosted its position in United Therapeutics by 1.8% in the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock valued at $961,000 after buying an additional 48 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,800 shares of the business's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the transaction, the chief financial officer now directly owns 6,978 shares in the company, valued at approximately $2,442,300. The trade was a 52.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the business's stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $367.36, for a total transaction of $2,828,672.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at $13,485,785.60. This represents a 17.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 119,340 shares of company stock valued at $44,765,530 over the last three months. 11.90% of the stock is owned by company insiders.

United Therapeutics Price Performance

Shares of UTHR traded up $0.20 on Friday, reaching $361.81. The company's stock had a trading volume of 293,245 shares, compared to its average volume of 268,515. United Therapeutics Co. has a 12-month low of $208.62 and a 12-month high of $417.82. The stock has a market capitalization of $16.15 billion, a P/E ratio of 15.89, a PEG ratio of 1.05 and a beta of 0.54. The stock's 50 day simple moving average is $369.94 and its two-hundred day simple moving average is $342.19.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.16 by $0.23. The firm had revenue of $748.90 million for the quarter, compared to analysts' expectations of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.38 earnings per share. Analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on UTHR. The Goldman Sachs Group raised their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a "neutral" rating in a research note on Friday, November 1st. TD Cowen lifted their price objective on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Wells Fargo & Company upped their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a report on Tuesday, August 20th. Jefferies Financial Group boosted their price target on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Finally, StockNews.com upgraded shares of United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.